Relenza, the new flu treatment controversially excluded from the NHS because
a panel decided it was not cost-effective, can cause breathing difficulties in
patients with asthma. Glaxo Wellcome, which makes the drug, warned doctors of
the danger last week. The company says the number of people who have suffered
breathing difficulties after taking the drug is tiny, and that the warning is
simply a precaution. But the news is unfortunate, given that flu patients with
chronic lung disease are among the ones most likely to benefit from effective
influenza treatments.
More from New Scientist
Explore the latest news, articles and features
Technology
Test moderators use AI-generated writing to judge literacy standards
News
Mind
THC in cannabis may reduce nightmares in people with PTSD
News
Environment
Fishers detonate a bomb every hour on one Indonesian coral reef
News
Environment
How bad is the UK drought and how long will it continue?
News
Popular articles
Trending New Scientist articles